Health
AlzeCure Abstract on NeuroRestore ACD856 accepted at the Alzheimer's conference AP/PD 2026
STOCKHOLM, SE / ACCESS Newswire / February 3, 2026 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR)(STO:ALZCUR)(FRA:AC6), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease ...
About this update from Alzecure Pharma Ab
[{"type":"text","content":"STOCKHOLM, SE / ACCESS Newswire / February 3, 2026 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR)(STO:ALZCUR)(FRA:AC6), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that an abstract with preclinical data on NeuroRestore ACD856 which examines in more detail the biological effects of the substance mediated by its mechanism of action has been accepted for presentation at the international conference AD/PD 2026, to be held in Copenhagen on March 17-21.","length":564,"tagName":"p"},{"type":"text","content":"The abstract, titled Characterization of mechanisms of action of NeuroRestore ACD856, a positive allosteric modulator of Trk-receptors under clinical development for Alzheimer's disease, will be presented at the International Conference on Alzheimer's, Parkinson's and Related Neurological Diseases (AD/PD 2026) by Christina Parrado-Fernández, Senior Scientist at AlzeCure. Other authors are Azita Rasti, Maria Backlund, Veronica Lidell, Nather Madjid, Gunnar Nordvall, Johan Sandin and Pontus Forsell from AlzeCure.","length":528,"tagName":"p"},{"type":"text","content":"The presentation includes new preclinical results demonstrating that ACD856, the lead drug candidate within the NeuroRestore platform, affects Trk receptor-mediated signaling pathways in a dose- and time-dependent manner. Data also demonstrate that ACD856 exhibits potent and significant positive effects on cognition and depression.","length":333,"tagName":"p"},{"type":"text","content":""The results show that ACD856 has a clear biological effect on NGF and BDNF signaling. These neurotrophins play an important role in the function and survival of nerve cells in the brain, and are negatively affected in diseases such as Alzheimer's. The results show positive functional effects, such as improved memory function," said Cristina Parrado, Senior Scientist at AlzeCure.","length":396,"tagName":"p"},{"type":"text","content":"Preclinical studies have shown that AlzeCure's drug candidates in the NeuroRestore platform strengthen communication between nerve cells and improve cognitive ability, including learning and memory functions. Previous preclinical results from AlzeCure also show neuroprotective, anti-inflammatory and disease-modifying ef...